Arvinas Stock Forecast, Price & News

-4.77 (-6.03 %)
(As of 06/22/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume2.16 million shs
Average Volume467,549 shs
Market Capitalization$3.64 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ARVN News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

Arvinas logo

About Arvinas

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.71 out of 5 stars

Medical Sector

272nd out of 2,105 stocks

Pharmaceutical Preparations Industry

132nd out of 832 stocks

Analyst Opinion: 4.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Arvinas (NASDAQ:ARVN) Frequently Asked Questions

Is Arvinas a buy right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Arvinas stock.
View analyst ratings for Arvinas
or view top-rated stocks.

What stocks does MarketBeat like better than Arvinas?

Wall Street analysts have given Arvinas a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Arvinas wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Arvinas' next earnings date?

Arvinas is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Arvinas

How were Arvinas' earnings last quarter?

Arvinas, Inc. (NASDAQ:ARVN) posted its quarterly earnings data on Monday, May, 3rd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by $0.01. Arvinas had a negative trailing twelve-month return on equity of 33.38% and a negative net margin of 656.61%.
View Arvinas' earnings history

How has Arvinas' stock been impacted by COVID-19?

Arvinas' stock was trading at $44.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ARVN shares have increased by 68.7% and is now trading at $74.34.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ARVN?

12 brokerages have issued 1 year price objectives for Arvinas' shares. Their forecasts range from $93.00 to $150.00. On average, they expect Arvinas' stock price to reach $119.15 in the next year. This suggests a possible upside of 60.3% from the stock's current price.
View analysts' price targets for Arvinas
or view top-rated stocks among Wall Street analysts.

Who are Arvinas' key executives?

Arvinas' management team includes the following people:
  • Dr. John G. Houston Ph.D., CEO, Pres & Director (Age 61, Pay $1.02M)
  • Mr. Sean A. Cassidy CPA, M.B.A., CPA, CFO & Treasurer (Age 51, Pay $617k)
  • Dr. Ian Taylor Ph.D., Chief Scientific Officer (Age 58, Pay $657.7k)
  • Dr. Ronald A. Peck, Chief Medical Officer
  • Dr. Craig M. Crews, Founder, Chief Scientific Advisor & Member of Scientific Advisory Board
  • Mr. Matthew Batters J.D., Gen. Counsel (Age 45)
  • Dr. Robert Kleinfield, Chief Devel. Officer
  • Dr. Randy Teel, VP of Corp. Devel. (Age 42)
  • Mr. Steve Weiss, VP of HR (Age 52)
  • Ms. Marcia Dougan Moore, Sr. VP of Strategic Operations (Age 55)

Who are some of Arvinas' key competitors?

What other stocks do shareholders of Arvinas own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

When did Arvinas IPO?

(ARVN) raised $100 million in an IPO on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

What is Arvinas' stock symbol?

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Who are Arvinas' major shareholders?

Arvinas' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.13%), Price T Rowe Associates Inc. MD (4.87%), Bellevue Group AG (4.23%), JPMorgan Chase & Co. (3.53%), RTW Investments LP (3.31%) and Gilder Gagnon Howe & Co. LLC (3.24%). Company insiders that own Arvinas stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Ventures Iii LP 5Am.
View institutional ownership trends for Arvinas

Which major investors are selling Arvinas stock?

ARVN stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Gilder Gagnon Howe & Co. LLC, Millennium Management LLC, Ikarian Capital LLC, Rock Springs Capital Management LP, Bellevue Group AG, Voloridge Investment Management LLC, and Sectoral Asset Management Inc. Company insiders that have sold Arvinas company stock in the last year include Ian Taylor, John G Houston, Ronald Peck, and Sean A Cassidy.
View insider buying and selling activity for Arvinas
or view top insider-selling stocks.

Which major investors are buying Arvinas stock?

ARVN stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., EcoR1 Capital LLC, Wasatch Advisors Inc., BlackRock Inc., Price T Rowe Associates Inc. MD, Renaissance Technologies LLC, JPMorgan Chase & Co., and Morgan Stanley. Company insiders that have bought Arvinas stock in the last two years include Briggs Morrison, Liam Ratcliffe, and Timothy M Shannon.
View insider buying and selling activity for Arvinas
or or view top insider-buying stocks.

How do I buy shares of Arvinas?

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arvinas' stock price today?

One share of ARVN stock can currently be purchased for approximately $74.34.

How much money does Arvinas make?

Arvinas has a market capitalization of $3.64 billion and generates $21.80 million in revenue each year. The company earns $-119,330,000.00 in net income (profit) each year or ($3.02) on an earnings per share basis.

How many employees does Arvinas have?

Arvinas employs 179 workers across the globe.

What is Arvinas' official website?

The official website for Arvinas is

Where are Arvinas' headquarters?

Arvinas is headquartered at 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511.

How can I contact Arvinas?

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at (203) 535-1456 or via email at [email protected]

This page was last updated on 6/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.